New data on quality of life and cost savings for everlinQ endoAVF System


A recent healthcare analysis shows that a novel, catheter-based endovascular system for creating haemodialysis access offers quality-of-life benefits and cost savings compared to the traditional surgical approach in end-stage renal disease patients. The retrospective analysis comparing the everlinQ endoAVF System from TVA Medical with surgical arteriovenous fistula creation was presented at ISPOR 2018 (19–23 May, Baltimore, USA), a leading global conference for health economics and outcomes research.

Compared to surgical arteriovenous fistula patients, endoAVF patients had nearly double the number of days with a functioning fistula for dialysis; spent less time using a central venous catheter (83 vs. 261 days), leading to improvements in quality-adjusted life years (QALYs) (0.574 QALYs vs. 0.548 QALYs), and needed fewer interventions (0.55 vs. 4.38), resulting in an average of 90% lower related costs ($1,271 vs. $13,031) in the first year after receiving an arteriovenous fistula.


“Over 7% of the Medicare budget is spent on managing patients with end-stage renal disease. Non-functional arteriovenous fistulae lead to prolonged central venous catheter use, increasing the risk of infection and hospitalisation and contributing to the rising costs of treating haemodialysis patients. Procedures that facilitate a functional fistula, improve patient outcomes and save costs are an important advancement for patients and payers,” says Adam L Berman, CEO of TVA Medical. “We are encouraged by the results of this analysis and the benefit for patients.”

The retrospective analysis compared endoAVF patients from the Novel Endovascular Access Trial (NEAT, NCT02036671) with propensity-score matched surgical arteriovenous fistula patients from the US Renal Data System for one year after fistula creation.


Please enter your comment!
Please enter your name here